ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Heart disease"

  • Abstract Number: 2964 • 2015 ACR/ARHP Annual Meeting

    Influences of Various Factors on Survival of Patients Treated with Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Patients with Connective Tissue Diseases

    Sumiaki Tanaka1, Yu Matsueda2, Eisuke Ogawa1, Jun Okada3 and Shunsei Hirohata1, 1Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, 2Rheumatology and Infectious diseases, Kitasato University School of Medicine, Kanagawa, Japan, 3Rheumatology, Kitasato University Hospital, Sagamihara, Japan

    Background/Purpose: In patients with connective tissue disease (CTD), especially systemic sclerosis (SSc), several mechanisms have been implicated for the development of pulmonary hypertension (PH), including…
  • Abstract Number: 2991 • 2015 ACR/ARHP Annual Meeting

    Evaluation of Serum Levels of Adipokines and Interleukines in Pericardial Effusion Related to Systemic Sclerosis

    Angela Chialà1, Cinzia Rotondo1, Maria Grazia Anelli1, Emanuela Praino1, Luca Cantarini2, Crescenzio Scioscia1, Margherita Giannini1, Giovanni Lapadula1 and Florenzo Iannone1, 1DIM, Rheumatology Unit, Bari, Italy, 2Univ Siena, Siena, Italy

    Background/Purpose: Pericardial involvement is common in rheumatic disease, as rheumatoid arthritis, lupus erythematosus, mixed connective disease and systemic sclerosis. Few data are available about pathogenesis…
  • Abstract Number: 911 • 2015 ACR/ARHP Annual Meeting

    Patients with Rheumatoid Arthritis Are at Increased Risk of Both Ischemic and Non-Ischemic Heart Failure

    Ängla Mantel1, Marie Holmqvist1, Daniel Andersson2,3, Lars Lund2,3 and Johan Askling4,5, 1Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Department of medicine, Karolinska Institutet, Cardiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Karolinska university hospital, Cardiology Unit, Karolinska University Hospital, Stockholm, Sweden, 4Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, 5Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Studies among unselected patients with rheumatoid arthritis (RA) suggest increased risks of both ischemic and non-ischemic heart failure (HF). Since the risk of these…
  • Abstract Number: 1534 • 2015 ACR/ARHP Annual Meeting

    Temporal Trends and Outcomes of Acute Myocardial Infarction in Rheumatoid Arthritis Hospitalizations

    Narender Annapureddy1, Achint Patel2, Rabi Yacoub3, Krishna Pakanati4, Shiv Agarwal5, Priya Simoes6, Shaan Patel3, Sunil Kamat7, Alexandre Benjo8 and Girish Nadkarni9, 1Rheumatology and Immunology, Vanderbilt University, Nashville, TN, 2Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, 3Icahn School of Medicine at Mount Sinai, New York, NY, 4Gateway Medical Center, Clarksville, TN, 5Cardiology, University of Arkansas Medical Sciences, Little Rock, AR, 6Internal Medicine, St.Lukes Roosevelt Hospital Center at Mount Sinai, New York, NY, 7Critical Care, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India, 8Ochsner Clinic Foundation, New Orleans, NY, 9Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiac mortality. With better treatment modalities, some studies suggest that infarction (AMI) mortality in RA…
  • Abstract Number: 1886 • 2015 ACR/ARHP Annual Meeting

    Myocardial Fibrosis Detected By Magnetic Resonance Imaging Is a Predictor of Heart Failure in Systemic Sclerosis (SSc) Patients

    Tatiana Sofia Rodriguez-Reyna1, Martha Morelos-Guzmán2, Pamela Mercado Velazquez3, Pablo Henrandez-Reyes4, Karla Montero-Duarte5, Cynthia Martinez-Reyes6, Carlos Reyes-Utrera6 and Carlos Nunez Alvarez3, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Radiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 3Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico, 4Department of Cardiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 5Department of Imaging and Radiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 6Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

    Background/Purpose: In previous studies we showed that prevalence of myocardial fibrosis in SSc patients is 45% and is associated to diffuse disease (dcSSc) and lower…
  • Abstract Number: 2905 • 2014 ACR/ARHP Annual Meeting

    The IL-6/Th17 Axis Promotes Autoantibody-Associated Autoimmune Valvular Carditis in Mice

    Jennifer L. Auger1, Brianna J. Engelson2, Yaya Wang3, Erik J. Peterson4 and Bryce A. Binstadt5, 1Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, 2Pediatrics, University of Minnesota, Minneapolis, MN, 3Medicine, University of Minnesota, Minneapolis, MN, 4University of Minnesota, Minneapolis, MN, 5Pediatric Rheumatology, University of Minnesota, Minneapolis, MN

    Background/Purpose: Autoimmune valvular carditis occurs in patients with systemic lupus erythematosus, rheumatoid arthritis and rheumatic fever, but the pathogenic mechanisms remain incompletely defined. Spontaneous autoimmune…
  • Abstract Number: 1909 • 2014 ACR/ARHP Annual Meeting

    Incidence of Congestive Heart Failure in Subjects with Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor Drugs: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

    Alper van Sijl1, Mamas Mamas2, Mark Lunt3,4, . BSRBR Control Centre Consortium3, Kath Watson5, Deborah P. Symmons3,6 and Kimme L. Hyrich7, 1Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 2Manchester Heart Centre, Manchester Royal Infirmary, Oxford Road, Manchester, UK; Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 5Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 6Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 7Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom

    Background/Purpose Subjects with rheumatoid arthritis (RA) are at a higher risk of developing cardiovascular (CV) disease compared to the general population, with an increased incidence…
  • Abstract Number: 1681 • 2014 ACR/ARHP Annual Meeting

    Heart Transplantation in 6 Patients with Systemic Sclerosis and a Primary Cardiac Involvement

    Alena Ikic1, Emmanuel Chatelus2, Eric Epailly3, Hélène Kremer3, Jean Sibilia2, Jacques Gottenberg4, Sabine Pattier5, Erwan Flecher6, Céline Goeminne7 and Thierry Martin1, 1Strasbourg University Hospital, Strasbourg, France, 2Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, 3Cardiology, Strasbourg University Hospital, Strasbourg, France, 4Rheumatology, Strasbourg University Hospital, Strasbourg, France, 5Cardiology, Nantes University Hospital, Nantes, France, 6Cardiac Surgey, Rennes University Hospital, Rennes, France, 7Cardiology, Lille University Hospital, Lille, France

    Background/Purpose: There is no specific treatment for primary cardiac involvement in SSc. Even if heart transplantation is an option, only 1 case have been reported1.…
  • Abstract Number: 1253 • 2014 ACR/ARHP Annual Meeting

    Anakinra – a Promising New Therapy for Idiopathic Recurrent Pericarditis

    Sonia Jain1, Charat Thongprayoon2, Raul Espinosa1, Sharonne Hayes1, Kyle Klarich1, Kevin Moder3, Nandan Anavekar1, Jae Oh1 and Eric L. Matteson4, 1Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 2Department of Medicine, Mayo clinic, Rochester, MN, 3Division of Rheumatology, Mayo Clinic, Rochester, MN, 4Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose Idiopathic recurrent pericarditis (IRP) is a debilitating condition that can be recalcitrant to conventional therapy. Some patients develop steroid dependency with the attendant risks…
  • Abstract Number: 738 • 2014 ACR/ARHP Annual Meeting

    Troponin T as a Diagnostic and Prognostic Biomarker of Primary Cardiac Involvement in Systemic Sclerosis

    Silvia Laura Bosello, Giacomo De Luca, Federico Parisi, Giorgia Berardi, Manuela Rucco, Giovanni Canestrari and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy

    Background/Purpose .Heart involvement is common in Systemic Sclerosis (SSc), even if often clinically silent, and represents one of the leading cause of death in these…
  • Abstract Number: 2834 • 2013 ACR/ARHP Annual Meeting

    Maternal data Analysis Of The French Registry Of 205 Cases Of Immune Congenital Heart Block (neonatal lupus)

    Kateri Levesque1, Nathalie Morel2, Gaëlle Guettrot-Imbert3, Mohamed Hamidou4, Jean Loup Pennaforte5, Pauline Orquevaux5, Jean-Charles Piette6, Christophe Deligny7, Zahir Amoura8, Olivier Meyer9, Olivier Fain10, Agathe Masseau11, Holly Bezanahary12, Pascal Cathebras13, Elizabeth Diot14, Yves Dulac15, Loic Guillevin16, Eric Hachulla17, Jean-Louis Pasquali18, Anne Besancon-Bergelin19, Bernard Bonnotte20, Jérome Lebidois21, Alice Maltret22, Elisabeth Villain22 and Nathalie Costedoat-Chalumeau23, 1Medicine Interne, Hopital Cochin, Paris, France, 2Internal Medicine, COCHIN, Paris, France, 3Internal Medicine, Centre Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, 4CHU Hôtel Dieu, Nantes, Nantes, France, 5Hu Robert Debre, CHU Reims, Reims, France, 6Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, 7Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, 8Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, 9Rheumatology, Bichat University Hospital, Paris, France, 10Internal Medicine, Jean Verdier Hospital, Bondy, France, 11Internal Medicine Department, Nantes University Hospital, Nantes, France, 12Internal Medicine, University Hospital of Limoges, Limoges, France, 13Internal Medicine, University Hospital St Etienne, St Etienne, France, 14Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, 15University Hospital Toulouse, Paris, France, 16Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, 17Internal Medicine, University Hospital Lilles, Lille CEDEX, France, 18Strasbourg University, Hospital, CNRS UPR 3572, Strasbourg, France, 19Internal Medicine, Le Mans Hospital, Le Mans, France, 20Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, 21Cardiac Institute, Paris, France, 22Cardiology, Groupe Hospitalier Necker - Enfants Malades, Paris, France, 23Internal Medicine, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France

    Background/Purpose: Congenital heart block (CHB) occurs in 1 to 2 % of pregnancies exposed to anti-SSA antibodies.  Few data are available regarding the risk of…
  • Abstract Number: 2589 • 2013 ACR/ARHP Annual Meeting

    Scleroderma Patients With Pulmonary Hypertension and Increased Pulmonary Capillary Wedge Pressure In The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma (PHAROS) Cohort

    Matthew R. Lammi1,2, Lesley Ann Saketkoo3,4, Jessica K. Gordon5, Paula Lauto6 and Virginia D. Steen7, 1Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 2Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, 3Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, 4LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 5Rheumatology, Hospital for Special Surgery, New York, NY, 6Pulmonary and Critical Care Medicine, LSU Health Sciences Center, New Orleans, LA, 7Department of Rheumatology, Georgetown University Medical Center, Washington, DC

    Background/Purpose: Systemic sclerosis (SSc) commonly leads to pulmonary hypertension (PH), which may be associated with left heart disease and an elevated pulmonary capillary wedge pressure…
  • Abstract Number: 2038 • 2013 ACR/ARHP Annual Meeting

    Congenital Heart Block Related With Maternal Autoimmune Diseases: Descriptive Analysis Of a Series Of 17 Cases

    Pamela Inés Doti1, Ona Escoda2, Sergi Cesar-Diaz3, Narcís Masoller4, Irene Teixidó4, Josep Maria Martinez4, Georgia Sarquella-Brugada5 and Gerard Espinosa2, 1Department of Autoimmune Diseases, Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, 2Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, 3Arrhythmia Unit, Cardiology Section, Arrhythmia Unit, Cardiology Section, Hospital Sant Joan de Déu, Barcelona, Barcelona, Spain, 4Maternal Fetal Medicine Department, Hospital Clínic, Bacelona, Barcelona, Spain, 5Arrhythmia Unit, Cardiology Section, Hospital Sant Joan de Déu, Barcelona, Barcelona, Spain

    Background/Purpose: To describe the clinical characteristics of maternal autoimmune-mediated fetal congenital heart block (CHB) in a cohort of pregnant women from an Autoimmune Diseases Pregnancy…
  • Abstract Number: 1277 • 2013 ACR/ARHP Annual Meeting

    A Pilot Study Of Young Adults With Juvenile Dermatomyositis With Decreased Nailfold Capillary End Row Loops:  Brachial Artery Reactivity and Oxidized Lipids

    Lauren M. Pachman1,2, Maureen A. McMahon3, Tamar Polonsky4, Gabrielle A. Morgan1, Maria Amoruso5 and Chiang-Ching Huang6, 1Cure JM Myositis Center, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center, Chicago, IL, 2Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 4Cardiology, University of Chicago Medicine, Chicago, IL, 5Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Cure JM Myositis Center, Chicago, IL, 6Zilber School of Public Health, University of Wisconsin at Milwaukee, Milwaukee, WI

    Background/Purpose: Our center previously reported increased carotid intima media thickness, and lower high-density lipoprotein (HDL) levels in young or middle-age adults with a history of…
  • Abstract Number: 1080 • 2013 ACR/ARHP Annual Meeting

    Incidence Of Coronary Heart Disease Associated With Arthritis: A Canadian Population-Based Cohort Study

    Orit Schieir1, S. Hogg-Johnson2, Richard H Glazier3 and Elizabeth M. Badley4, 1Epidemiology, University of Toronto, Toronto, ON, Canada, 2Institute for Work and Health, Toronto, ON, Canada, 3nstitute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 4Division of Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Several individual types of arthritis have been associated with increased coronary heart disease (CHD) morbidity in clinical studies, but whether arthritis overall increases the…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology